Although some mutations in KIT/PDGFRA have been suggested to be associated with the sensitivity of GIST to imatinib therapy, obvious differences in drug response were observed in some patients even with “the same” mutation in KIT/PDGFRA. Here, KIT is linked to gastrointestinal stromal tumor.